CHD5 mRNA and protein expression are significantly lower in ALL patients in comparison with normal mononuclear cells (NMCs); thus, CHD5 can be used as a biomarker panel for hematopoietic malignancies even for therapeutic approaches (Figes.1A, 2) (33). Here, CHD5 is linked to acute lymphoblastic leukemia.